{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:16:50Z","timestamp":1707524210117},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,11]]},"DOI":"10.7759\/cureus.12642","type":"journal-article","created":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T07:30:31Z","timestamp":1610436631000},"source":"Crossref","is-referenced-by-count":1,"title":["Uterine Carcinosarcoma in a Young Female: Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"Noha N","family":"Soror","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Woredekal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori","family":"Hemrock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e318176157c","article-title":"Uterine carcinosarcomas and grade 3 endometrioid cancers. Evidence for distinct tumor behavior","volume":"112","author":"Bansal N","year":"2008","unstructured":"Bansal N, Herzog TJ, Seshan VE, Schiff PB, Burke WM, Cohen CJ, Wright J. Uterine carcinosarcomas and grade 3 endometrioid cancers. Evidence for distinct tumor behavior. Obstet Gynecol. 2008, 112:64-70. 10.1097\/AOG.0b013e318176157c","journal-title":"Obstet Gynecol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11484","article-title":"Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus","volume":"98","author":"Sherman ME","year":"2003","unstructured":"Sherman ME, Devesa SS. Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer. 2003, 98:176-186. 10.1002\/cncr.11484","journal-title":"Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.03.041","article-title":"Uterine carcinosarcoma: a review of the literature","volume":"137","author":"Cantrell LA","year":"2015","unstructured":"Cantrell LA, Blank SV, Duska LR. Uterine carcinosarcoma: a review of the literature. Gynecol Oncol. 2015, 137:581-588. 10.1016\/j.ygyno.2015.03.041","journal-title":"Gynecol Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1159\/000494335","article-title":"Uterine carcinosarcomas - diagnosis and management","volume":"41","author":"Denschlag D","year":"2018","unstructured":"Denschlag D, Ulrich UA. Uterine carcinosarcomas - diagnosis and management. Oncol Res Treat. 2018, 41:675-679. 10.1159\/000494335","journal-title":"Oncol Res Treat"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2003.12.029","article-title":"Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999","volume":"93","author":"Brooks SE","year":"2004","unstructured":"Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol. 2004, 93:204-208. 10.1016\/j.ygyno.2003.12.029","journal-title":"Gynecol Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30729","article-title":"Association between hyperinsulinemia and increased risk of cancer death in nonobese and obese people: a population-based observational study","volume":"141","author":"Tsujimoto T","year":"2017","unstructured":"Tsujimoto T, Kajio H, Sugiyama T. Association between hyperinsulinemia and increased risk of cancer death in nonobese and obese people: a population-based observational study. Int J Cancer. 2017, 141:102-111.  10.1002\/ijc.30729","journal-title":"Int J Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.4638","article-title":"Addressing the role of obesity in endometrial cancer risk, prevention, and treatment","volume":"34","author":"Onstad MA","year":"2016","unstructured":"Onstad MA, Schmandt RE, Lu KH. Addressing the role of obesity in endometrial cancer risk, prevention, and treatment. J Clin Oncol. 2016, 34:4225-4230. 10.1200\/JCO.2016.69.4638","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1614120113","article-title":"Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition","volume":"25","author":"Siming Zhao","year":"2016","unstructured":"Siming Zhao, Stefania Bellone, Salvatore Lopez, et al.. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition. Proc Natl Acad Sci U S A. 2016, 25:12238-12243. 10.1073\/pnas.1614120113","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e3182979b27","article-title":"Uterine and ovary carcinosarcomas: outcome, prognosis factors, and adjuvant therapy","volume":"38","author":"Pacaut C","year":"2015","unstructured":"Pacaut C, Bourmaud A, Rivoirard R, et al.. Uterine and ovary carcinosarcomas: outcome, prognosis factors, and adjuvant therapy. Am J Clin Oncol. 2015, 38:272-277. 10.1097\/COC.0b013e3182979b27","journal-title":"Am J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.07.3281","article-title":"Primary malignant mixed Mullerian tumor of the uterus: findings on sonography, CT, and gadolinium-enhanced MRI","volume":"191","author":"Teo SY","year":"2008","unstructured":"Teo SY, Babagbemi KT, Peters HE, Mortele KJ. Primary malignant mixed Mullerian tumor of the uterus: findings on sonography, CT, and gadolinium-enhanced MRI. AJR Am J Roentgenol. 2008, 191:278-283. 10.2214\/AJR.07.3281","journal-title":"AJR Am J Roentgenol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.08.060","article-title":"Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma","volume":"107","author":"Huang GS","year":"2007","unstructured":"Huang GS, Chiu LG, Gebb JS, Gunter MJ, Sukumvanich P, Goldberg GL, Einstein MH. Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma. Gynecol Oncol. 2007, 107:513-517. 10.1016\/j.ygyno.2007.08.060","journal-title":"Gynecol Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(03)01561-X","article-title":"Malignant mixed M\u00fcllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome","volume":"58","author":"Callister M","year":"2004","unstructured":"Callister M, Ramondetta LM, Jhingran A, Burke TW, Eifel PJ. Malignant mixed M\u00fcllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys. 2004, 58:786-796. 10.1016\/S0360-3016(03)01561-X","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.8326","article-title":"Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study","volume":"28","author":"Powell MA","year":"2010","unstructured":"Powell MA, Filiaci VL, Rose PG, et al.. Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. J Clin Oncol. 2010, 28:2727-2731. 10.1200\/JCO.2009.26.8326","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30079-2","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial","volume":"19","author":"de Boer SM","year":"2018","unstructured":"de Boer SM, Powell ME, Mileshkin L, et al.. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018, 19:295-309. 10.1016\/S1470-2045(18)30079-2","journal-title":"Lancet Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/48130-uterine-carcinosarcoma-in-a-young-female-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:28:02Z","timestamp":1707506882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/48130-uterine-carcinosarcoma-in-a-young-female-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,11]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.12642","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,11]]}}}